REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD - Synopsis below extracted from the video transcript.
The REGN5458 trial is a Phase 1 study of a bispecific antibody in patients with relapsed or refractory multiple myeloma (RRMM). The antibody, BCMAxCD3, targets the B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, helping to activate the immune system to attack the cancer cells.
Dr. Naresh Bumma, a hematologist and oncologist, discusses the promising results of the trial in a video presentation. The study included 42 patients with RRMM who had received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
The overall response rate (ORR) in the study was 82%, with a very good partial response (VGPR) rate of 57% and a complete response (CR) rate of 7%. The median progression-free survival (PFS) was 9.7 months, and the median overall survival (OS) had not been reached at the time of the data cutoff.
The most common adverse events (AEs) reported in the study were cytokine release syndrome (CRS) and neurotoxicity. However, these were mostly manageable with supportive care and did not lead to treatment discontinuation.
Read The Full Transcript and Watch The Video Here
Dr. Bumma notes that the results of the REGN5458 trial are particularly exciting given the advanced stage of disease in the patients enrolled, with many having exhausted all other available treatment options. He also highlights the potential for BCMAxCD3 to be used in combination with other agents, such as checkpoint inhibitors or CAR T-cell therapies, to further enhance its efficacy.
In conclusion, the REGN5458 trial provides promising results for a new treatment option in patients with RRMM. The BCMAxCD3 bispecific antibody offers a novel mechanism of action for activating the immune system against cancer cells, and its potential use in combination with other therapies warrants further investigation.
